Drugs / UTTR1147A
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02833389 | Nov 2016 → Nov 2018 | chronic ulcer of skin | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02749630 | Apr 2016 → Feb 2020 | Crohn disease, ulcerative colitis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 23 trials · 2 missed | ||||||
| Phase 2 | NCT04386616 | Jun 2020 → Jan 2021 | pneumonia | Genentech, Inc. | Completed | Missed primary |
| Phase 2 | NCT03650413 | Jan 2019 → Jul 2022 | Crohn disease, ulcerative colitis | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03558152 | Oct 2018 → Dec 2021 | ulcerative colitis | Genentech, Inc. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UTTR1147A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03650413 ↗ |
| Action | Activate | “Efmarodocokin alfa (UTTR1147A) is a fusion protein agonist” PMID 36732049 ↗ Feb 2023 |
| Modality | Protein / enzyme biologic | “Efmarodocokin alfa (UTTR1147A) is a fusion protein agonist” PMID 36732049 ↗ Feb 2023 |
| Route | Intravenous | “repeat intravenous dosing of efmarodocokin alfa” PMID 36732049 ↗ Feb 2023 |